17 results on '"Jarius S"'
Search Results
2. Autoantikörperassoziierte autoimmune Enzephalitiden und Zerebellitiden: Klinik, Diagnostik und Therapie
- Author
-
Lewerenz, J., Jarius, S., Wildemann, B., Wandinger, K.-P., and Leypoldt, F.
- Published
- 2016
- Full Text
- View/download PDF
3. Biopsie bei tumorverdächtiger spinaler Raumforderung: Fallstrick Neuromyelitis optica
- Author
-
Ringelstein, M., Aktas, O., Harmel, J., Prayer, D., Jarius, S., Wildemann, B., Hartung, H.-P., Salhofer-Polanyi, S., Leutmezer, F., and Rommer, P.S.
- Published
- 2014
- Full Text
- View/download PDF
4. Neuromyelitis optica
- Author
-
Wildemann, B., Jarius, S., and Paul, F.
- Published
- 2013
- Full Text
- View/download PDF
5. Susac-Syndrom: Eine interdisziplinäre Herausforderung
- Author
-
Dörr, J., Jarius, S., Wildemann, B., Ringelstein, E.B., Schwindt, W., Deppe, M., Wandinger, K.P., Promesberger, J., Paul, F., and Kleffner, I.
- Published
- 2011
- Full Text
- View/download PDF
6. Diagnostik und Therapie der Neuromyelitis optica: Konsensusempfehlungen der Neuromyelitis optica Studiengruppe
- Author
-
Trebst, C., Berthele, A., Jarius, S., Kümpfel, T., Schippling, S., Wildemann, B., Wilke, C., and Neuromyelitis optica Studiengruppe (NEMOS)
- Published
- 2011
- Full Text
- View/download PDF
7. Neuromyelitis optica
- Author
-
Jarius, S. and Wildemann, B.
- Published
- 2007
- Full Text
- View/download PDF
8. Interferontherapie der Multiplen Sklerose: Synopsis der verschiedenen Applikationsformen
- Author
-
Jarius, S. and Hohlfeld, R.
- Published
- 2004
- Full Text
- View/download PDF
9. Susac-Syndrom.
- Author
-
Dörr, J., Jarius, S., Wildemann, B., Ringelstein, E.B., Schwindt, W., Deppe, M., Wandinger, K.P., Promesberger, J., Paul, F., and Kleffner, I.
- Subjects
BRAIN diseases ,DEAFNESS ,RETINAL artery ,ARTERIAL occlusions ,AUTOIMMUNITY - Abstract
Copyright of Der Nervenarzt is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2011
- Full Text
- View/download PDF
10. Diagnosis of Neuromyelitis Optica Spectrum Disorder (NMOSD) and MOG Antibody-Associated Disease (MOGAD).
- Author
-
Mewes D, Kuchling J, Schindler P, Khalil AAA, Jarius S, Paul F, and Chien C
- Subjects
- Humans, Central Nervous System, Neuromyelitis Optica diagnosis, Optic Neuritis, Autoimmune Diseases, Multiple Sclerosis diagnosis
- Abstract
Aquaporin-4 antibody-seropositive neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD; also termed MOG encephalomyelitis) are autoimmune diseases of the central nervous system. The typical initial manifestations in adult patients are optic neuritis and myelitis. Patients often present with additional involvement of the brain and brainstem, more so in the later stages of the disease. While NMOSD commonly follows a relapsing course, MOGAD can sometimes be monophasic. Differential diagnosis is challenging and relies particularly on radiological and serological findings. It is very important to distinguish these rare diseases from the more common neuroinflammatory disease, multiple sclerosis (MS), since treatment and long-term prognoses for NMOSD, MOGAD and MS differ greatly. The diversity of the symptoms and the extent of the diagnostic work-up necessitate close collaboration between ophthalmology, neurology, and radiology. This article provides an overview of the typical MRI findings and serological antibody diagnostics for NMOSD and MOGAD, supplemented with two exemplary case reports from clinical practice., Competing Interests: Friedemann Paul: Vortragshonorar/Reisekosten von Alexion, Guthy Jackson Charitable Foundation, Bayer, Biogen, Merck Serono, Sanofi Genzyme, Novartis, Viela Bio, Roche, UCB, Mitsubishi Tanabe, Celgene (nicht im Zusammenhang mit diesem Artikel); Forschungsgelder von Alexion, Bundesministerium für Bildung und Forschung, Deutsche Forschungsgemeinschaft, Einstein Foundation, Guthy Jackson Charitable Foundation, EU FP7 Framework Program, Biogen, Genzyme, Merck Serono, Novartis, Bayer, Roche, Parexel, Almirall (nicht im Zusammenhang mit diesem Artikel); akademischer Editor für PLoS ONE; Associate Editor für Neurology Neuroimmunology & Neuroinflammation; wissenschaftliche Konsultation for SanofiGenzyme, Biogen Idec, MedImmune, Shire, und Alexion; wissenschaftlicher Beirat für Celgene, Roche, UCB, Merck. Claudia Chien; Vortragshonorar von Bayer und Forschungsgelder von Novartis (nicht im Zusammenhang mit diesem Artikel)./Friedemann Paul: Speaker fees/travel costs from Alexion, the Guthy Jackson Charitable Foundation, Bayer, Biogen, Merck Serono, Sanofi Genzyme, Novartis, Viela Bio, Roche, UCB, Mitsubishi Tanabe, and Celgene (not related to this article); research funding from Alexion, the Federal Ministry of Education and Research, the German Research Foundation, the Einstein Foundation, the Guthy Jackson Charitable Foundation, the EU FP7 Framework Program, Biogen, Genzyme, Merck Serono, Novartis, Bayer, Roche, Parexel, and Almirall (not related to this article); academic editor for PLoS ONE; associate editor for Neurology Neuroimmunology & Neuroinflammation; academic consultant for SanofiGenzyme, Biogen Idec, MedImmune, Shire, and Alexion; member of scientific advisory board for Celgene, Roche, UCB, and Merck. Claudia Chien; speaker fees from Bayer and research funding from Novartis (not related to this article)., (Thieme. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
11. [Aquaporin 4 antibody-positive neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated encephalomyelitis. A brief review].
- Author
-
Jarius S and Wildemann B
- Subjects
- Adult, Aquaporin 4, Autoantibodies, Humans, Myelin-Oligodendrocyte Glycoprotein, Encephalomyelitis diagnosis, Encephalomyelitis therapy, Neuromyelitis Optica diagnosis, Neuromyelitis Optica therapy
- Abstract
Aquaporin 4 (AQP4) immunoglobulin (Ig)G-associated neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein immunoglobulin (Ig)G-associated encephalomyelitis (MOG-EM, also termed MOG antibody-associated disease, MOGAD) are important autoimmune differential diagnoses of multiple sclerosis (MS), which differ from MS with respect to optimum treatment and prognosis. AQP4 IgG-positive NMOSD take a relapsing course in virtually all cases and MOG-EM in at least 80% of adult cases. Both diseases can quickly lead to permanent disability if left untreated, although MOG-EM is associated with a better overall long-term prognosis. Antibody testing must be carried out by means of so-called cell-based assays. A number of red flags have been defined that must be checked prior to making a diagnosis of NMOSD or MOG-EM. Acute attacks are treated using high-dose glucocorticoids and plasma exchange or immunoadsorption. Rituximab and other immunosuppressants are used off-label for attack prevention. Recently, eculizumab, a C5 complement inhibitor, has been approved in the European Union (EU) for the treatment of patients with AQP4 IgG-positive NMOSD. This article gives a brief overview of the clinical and paraclinical features, pathology, treatment and prognosis of these rare disorders.
- Published
- 2021
- Full Text
- View/download PDF
12. [Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis: Diagnosis and Treatment].
- Author
-
Wildemann B, Horstmann S, Korporal-Kuhnke M, Viehöver A, and Jarius S
- Subjects
- Humans, Myelin-Oligodendrocyte Glycoprotein, Retrospective Studies, Aquaporin 4, Neuromyelitis Optica diagnosis, Optic Neuritis diagnosis, Optic Neuritis therapy
- Abstract
Optic neuritis (ON) is a frequent manifestation of aquaporin-4 (AQP4) antibody-mediated neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated encephalomyelitis (MOG-EM; also termed MOG antibody-associated disorders, MOGAD). The past few years have seen major advances in the diagnosis and treatment of these two relatively new entities: international diagnostic criteria for NMOSD and MOG-EM have been proposed, improved antibody assays developed, and consensus recommendations on the indications and methodology of serological testing published. Very recently, the results of four phase III trials assessing new treatment options for NMOSD have been presented. With eculizumab, a monoclonal antibody inhibiting complement factor C5, for the first time a relapse-preventing long-term treatment for NMOSD - which has so far mostly been treated off-label with rituximab, azathioprine, and other immunosuppressants - has been approved. Data from recent retrospective studies evaluating treatment responses in MOG-ON suggest that rituximab and other immunosuppressants are effective also in this entity. By contrast, many drugs approved for the treatment of multiple sclerosis (MS) have been found to be either ineffective or to cause disease exacerbation (e.g., interferon-β). Recent studies have shown that not only NMOSD-ON but also MOG-ON usually follows a relapsing course. If left untreated, both disorders can result in severe visual deficiency or blindness, though MOG-ON seems to have a better prognosis overall. Acute attacks are treated with high-dose intravenous methylprednisolone and, in many cases, plasma exchange (PEX) or immunoadsorption (IA). Early use of PEX/IA may prevent persisting visual loss and improve the long-term outcome. Especially MOG-ON has been found to be frequently associated with flare-ups, if steroids are not tapered, and to underlie many cases of "chronic relapsing inflammatory optic neuropathy" (CRION). Both NMOSD-ON and MOG-ON are often associated with simultaneous or consecutive attacks of myelitis and brainstem encephalitis; in contrast to earlier assumptions, supratentorial MRI brain lesions are a common finding and do not preclude the diagnosis. In this article, we review the current knowledge on the clinical presentation, epidemiology, diagnosis, and treatment of these two rare yet important differential diagnoses of both MS-associated ON und idiopathic autoimmune ON., Competing Interests: B. Wildemann erhielt Forschungsunterstützung durch das Bundesministerium für Bildung und Forschung (Klinisches Kompetenznetz Multiple Sklerose), die Dietmar-Hopp-Stiftung und Merck Serono; außerdem Forschungsunterstützung durch die Deutsche Forschungsgemeinschaft und die Klaus-Tschira-Stiftung; Forschungsunterstützung und Honorare für Vortragstätigkeiten und Reiseunterstützung von Merck Serono, Sanofi Genzyme, Novartis; und Honorare für Vortragstätigkeiten und/oder Reiseunterstützung von Alexion, Bayer, Biogen, Teva. S. Horstmann, S. Jarius, M. Korporal-Kuhnke und A. Viehöver geben keine Interessenkonflikte an., (Thieme. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
13. [Neuromyelitis optica].
- Author
-
Pache F, Wildemann B, Paul F, and Jarius S
- Subjects
- Adult, Aged, Diagnosis, Differential, Humans, Neuromyelitis Optica diagnostic imaging, Neuromyelitis Optica epidemiology, Neuromyelitis Optica pathology, Steroids therapeutic use, Neuromyelitis Optica therapy
- Abstract
Neuromyelitis optica (NMO) is an autoimmune disorder of the central nervous system (CNS), that predominantly affects the spinal cord and optic nerves. The neuropathologic hallmarks comprise deposits of antibodies and complement as well as loss of astrocytes, secondary degeneration of oligodendrocytes and neurons, and necrotic lesions with infiltration of neutrophilic and eosinophilic granulocytes. Pathognomonic serum autoantibodies against aquaporin-4 (AQP4-IgG, also termed NMO-IgG) are detectable in around 80 % of NMO patients and help to distinguish this rare entity from multiple sclerosis. The target antigen of NMO-IgG, the water channel protein AQP4, is ubiquitously expressed within the CNS and, as a component of the blood-brain barrier, highly concentrated in the endfeet of astrocytes. New international consensus criteria for NMO spectrum disorders, published in 2015, allow earlier diagnosis. Besides the two index manifestations, optic neuritis and transverse myelitis, involvement of the brainstem and diencephalon is relatively common in NMO. Inflammatory lesions of the area postrema typically cause intractable nausea and vomiting and/or hiccups. NMO mostly follows a relapsing course, especially in AQP4-IgG-positive cases. The treatment of acute exacerbations comprises intravenous methylprednisolone pulses and/or plasma exchange, and prevention of attacks requires long-term therapy with immunosuppressants and/or B-cell-depleting monoclonal antibodies., (© Georg Thieme Verlag KG Stuttgart · New York.)
- Published
- 2017
- Full Text
- View/download PDF
14. [Contribution of spinal cord biopsy to the differential diagnosis of longitudinal extensive transverse myelitis].
- Author
-
Ringelstein M, Aktas O, Harmel J, Prayer D, Jarius S, Wildemann B, Hartung HP, Salhofer-Polanyi S, Leutmezer F, and Rommer PS
- Subjects
- Adult, Diagnosis, Differential, Female, Humans, Reproducibility of Results, Sensitivity and Specificity, Myelitis, Transverse pathology, Neuromyelitis Optica pathology, Optic Neuritis pathology, Spinal Cord pathology
- Abstract
Background: Neuromyelitis optica spectrum disorders (NMOSD) are characterized by recurrent optic neuritis (ON) and longitudinally extensive transverse myelitis (LETM) as well as the serological detection of antibodies to aquaporin-4 (AQP4-ab). However, longitudinal extensive spinal cord lesions are not pathognomonic for NMOSD as they can also occur in systemic autoimmune diseases or mimic spinal cord tumors., Objectives/methods: We report a female patient who initially presented with a subacute spinal syndrome and a longitudinal spinal cord lesion on magnetic resonance imaging (MRI). As the brain MRI showed only unspecific white matter lesions and the cerebrospinal fluid was normal, a spinal cord biopsy was performed to exclude malignancies and revealed inflammatory demyelinating changes. In addition, after several deep vein thromboses and the detection of antiphospholipid antibodies, an antiphospholipid syndrome (APS) was diagnosed. Many years after the spinal cord biopsy, AQP4-ab were tested and found to be positive. We discuss the important differential diagnoses of LETM, give an overview of previously reported NMOSD cases in which a spinal cord biopsy was performed and highlight the crucial role of AQP4-ab testing for the differential diagnosis of longitudinal spinal cord lesions., Results/conclusions: Considering possible serious sequelae of spinal biopsy procedures, testing for AQP4-ab is mandatory in patients with unclear longitudinally extensive spinal cord lesions and should be performed preoperatively in all cases. In light of the heterogeneity of available assays, different detection methods should be used in doubtful cases. The relationship between NMO and APS needs further clarification; however, AQP4 IgG testing is recommended in patients presenting with APS and myelitis, optic neuritis or brainstem encephalitis.
- Published
- 2014
- Full Text
- View/download PDF
15. [Recent findings in pathogenesis, diagnostics and therapy of neuromyelitis optica].
- Author
-
Paul F, Jarius S, Glumm R, Wildemann B, Zipp F, and Aktas O
- Subjects
- Diagnosis, Differential, Humans, Immunosuppressive Agents therapeutic use, Prognosis, Neuromyelitis Optica diagnosis, Neuromyelitis Optica epidemiology, Neuromyelitis Optica genetics, Neuromyelitis Optica therapy
- Published
- 2008
- Full Text
- View/download PDF
16. [Diagnosis and treatment of multiple sclerosis. Update, 2003].
- Author
-
Jarius S, Hohlfeld R, and Voltz R
- Subjects
- Acute Disease, Adjuvants, Immunologic administration & dosage, Adjuvants, Immunologic therapeutic use, Analgesics administration & dosage, Analgesics therapeutic use, Anti-Inflammatory Agents administration & dosage, Anti-Inflammatory Agents therapeutic use, Antibodies, Monoclonal administration & dosage, Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal, Humanized, Azathioprine administration & dosage, Azathioprine therapeutic use, Controlled Clinical Trials as Topic, Cross-Over Studies, Glatiramer Acetate, Glucocorticoids administration & dosage, Glucocorticoids therapeutic use, Humans, Immunoglobulins, Intravenous therapeutic use, Immunosuppressive Agents therapeutic use, Interferon-beta administration & dosage, Interferon-beta therapeutic use, Longitudinal Studies, Methylprednisolone administration & dosage, Methylprednisolone therapeutic use, Mitoxantrone administration & dosage, Mitoxantrone therapeutic use, Multicenter Studies as Topic, Natalizumab, Peptides administration & dosage, Peptides therapeutic use, Pilot Projects, Prospective Studies, Recurrence, Time Factors, Multiple Sclerosis diagnosis, Multiple Sclerosis drug therapy, Multiple Sclerosis immunology
- Abstract
Multiple sclerosis (MS) is the most common demyelinating disease of the central nervous system. The etiology of MS is not yet fully understood. Besides of genetic predisposition and environmental factors autoimmune mechanisms seem to play a major role in the pathogenesis of MS. Therapy of MS therefore comprises mainly immunomodulatory and immuno-suppressive therapeutic concepts. Interferon beta (Avonex, Rebif, Betaferon/Betaseron) and Glatirameracetate (Copaxone) offer effective therapeutic options for the long-term treatment of relapsing-remitting MS. With Mitoxantron (Ralenova) being recently approved by the EMEA for the treatment of secondary-progressive and progressive-relapsing MS an effective therapeutic option is now available also for this group of patients. The standard treatment for acute MS continues to be the intravenous administration of high-dose methylprednisolone. Several promising new agents (Antegren, Statins) are currently under clinical examination and could expand the spectrum of available therapeutic strategies soon. Recent and ongoing trials as well as upcoming studies on MS therapy are summarized in this review.
- Published
- 2003
17. [Multiple sclerosis. Therapeutic nihilism is the wrong approach here].
- Author
-
Voltz R, Goebels N, Jarius S, and Hohlfeld R
- Subjects
- Clinical Trials as Topic, Humans, Immunosuppressive Agents adverse effects, Multiple Sclerosis, Chronic Progressive diagnosis, Multiple Sclerosis, Relapsing-Remitting diagnosis, Neurologic Examination drug effects, Immunization, Passive, Immunosuppressive Agents therapeutic use, Multiple Sclerosis, Chronic Progressive drug therapy, Multiple Sclerosis, Relapsing-Remitting drug therapy
- Abstract
The standard treatment for acute multiple sclerosis relapses continues to be the intravenous administration of high-dose methylprednisolone. For prophylactic purposes, immunomodulatory therapy with interferon beta or glatiramer acetate, immunoglobulins or azathioprine. Studies have shown that interferon beta not only reduces the frequency of relapses by one-third, but also significantly delays the second relapse, provided it is administrated early, that is, immediately following the first relapse. The reduction in the patient's quality of life caused by the illness can be appreciably improved by a whole series of symptomatic treatments. The ideal situation is a cooperative effort by an interdisciplinary team.
- Published
- 2002
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.